RightFit
Not yet recruitingPhase 1

Eplerenone and IOP in Healthy Adults

Effect of Short-Term Oral Eplerenone on Intraocular Pressure in Healthy Adult Volunteers: A Randomized, Double-Masked, Placebo-Controlled Crossover Study

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 50 Years
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether eplerenone lowers eye pressure in healthy adults ages 18–50. Each person will take eplerenone and a placebo (no active drug) during different study periods. Researchers will check eye pressure, blood pressure, kidney function, and blood potassium levels.

The goal of this clinical trial is to determine whether eplerenone lowers eye pressure in healthy adults. Eplerenone is a medication approved by the U.S. Food and Drug Administration for other medical conditions. Researchers will compare eplerenone with placebo (a substance containing no active drug) to determine whether eplerenone affects intraocular pressure (IOP). Participants will receive both eplerenone and placebo during different study periods and will have their eye pressure measured throughout the study. Blood pressure, kidney function, and potassium levels will also be monitored for safety.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You are 18–50 years old.
  • You have never had glaucoma (a disease that damages the eye’s main nerve) or high eye pressure.
  • Your starting eye pressure is 10–21 mmHg.
  • Your blood creatinine level (a measure of kidney function) is 1.3 mg/dL or less, and your blood potassium level is below 4.3 mmol/L.
  • Your systolic blood pressure (the top number) is above 110 mmHg.

Who can't join

  • You use steroid medicines applied to the body or taken to work throughout the body.
  • You have kidney disease or high potassium levels in your blood.
  • You take certain medicines that block a drug-processing protein called CYP3A, including clarithromycin, erythromycin, ketoconazole, itraconazole, fluconazole, verapamil, diltiazem, or ritonavir.
  • You are pregnant or breastfeeding.
  • You use medicines known to change eye pressure. These include eye medicines called prostaglandin analogs, alpha-2 agonists, Rho-kinase inhibitors, or parasympathomimetics, and beta-blockers or carbonic anhydrase inhibitors used in the eyes or throughout the body.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Adults aged 18-50 years * No history of glaucoma or ocular hypertension * Baseline intraocular pressure between 10-21 mmHg * Serum creatinine ≤1.3 mg/dL and serum potassium \<4.3 mmol/L * Systolic blood pressure \>110 mmHg Exclusion Criteria: * Use of topical or systemic steroids * Renal disease or hyperkalemia * Concomitant use of strong CYP3A inhibitors, including clarithromycin, erythromycin, ketoconazole, itraconazole, fluconazole, verapamil, diltiazem, or ritonavir * Pregnancy or breastfeeding * Use of medications known to affect intraocular pressure, including topical prostaglandin analogs, topical or systemic beta-blockers, topical alpha-2 agonists, topical or systemic carbonic anhydrase inhibitors, topical Rho-kinase inhibitors, or topical parasympathomimetics

Study sites (1)

FL